Related Experiment Video

Updated: May 25, 2026

Development and Application of Rapamycin-regulated Tyrosine Phosphatases
06:56

Development and Application of Rapamycin-regulated Tyrosine Phosphatases

Published on: September 6, 2024

Rapamycin resistance is linked to defective regulation of Skp2

Hana Totary-Jain1, Despina Sanoudou, Cula N Dautriche

  • 1Department of Physiology and Cellular Biophysics, the Clyde and Helen Wu Center for Molecular Cardiology, Columbia University College of Physicians & Surgeons, Columbia University, New York, USA. ht2167@columbia.edu

Cancer Research
|February 8, 2012
PubMed

Insights

Rapamycin sensitivity in tumors can be predicted by their ability to downregulate Skp2, a key protein. Silencing Skp2 enhances tumor cell sensitivity to rapamycin, offering a potential therapeutic strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The mammalian target of rapamycin (mTOR) pathway is crucial for regulating cell growth and is a target in cancer therapy.
  • mTOR inhibitors like rapamycin (sirolimus) show promise but face challenges due to rapamycin resistance in many tumors.

Purpose of the Study:

  • To identify biomarkers predicting tumor sensitivity to rapamycin.
  • To explore the role of Skp2 in modulating rapamycin response.
  • To evaluate Skp2 silencing as a therapeutic strategy against rapamycin-resistant tumors.

Main Methods:

  • Investigated the correlation between rapamycin treatment and Skp2 downregulation in tumors.
  • Utilized RNA interference (RNAi) to silence Skp2 expression in human tumor cells.
  • Assessed the in vitro sensitivity of tumor cells to rapamycin after Skp2 silencing.
  • Evaluated the in vivo efficacy of Skp2 silencing on tumor xenograft growth.

Main Results:

  • Rapamycin's ability to downregulate Skp2 identified tumors sensitive to its effects.
  • RNAi-mediated silencing of Skp2 significantly increased tumor cell sensitivity to rapamycin in vitro.
  • Skp2 silencing inhibited tumor xenograft growth in vivo, demonstrating therapeutic potential.

Conclusions:

  • Skp2 levels are a critical determinant of antitumor responses to mTOR inhibitors.
  • Skp2 serves as a potential pharmacogenomic marker for predicting rapamycin sensitivity.
  • Targeting Skp2 through silencing strategies offers a promising approach for overcoming rapamycin resistance in cancer therapy.

More Related Videos

Comparative Strategies for Ubiquitination Detection in Mammalian Cell Lysates Using SMAD2/SMURF2 as a Model09:00

Comparative Strategies for Ubiquitination Detection in Mammalian Cell Lysates Using SMAD2/SMURF2 as a Model

Published on: April 17, 2026

Use of Time-Lapse Microscopy and Stage-Specific Nuclear Depletion of Proteins to Study Meiosis in S. cerevisiae07:48

Use of Time-Lapse Microscopy and Stage-Specific Nuclear Depletion of Proteins to Study Meiosis in S. cerevisiae

Published on: October 11, 2022

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Restarting Stalled Replication Forks02:37

Restarting Stalled Replication Forks

DNA replication is initiated at sites containing predefined DNA sequences known as origins of replication. DNA is unwound at these sites by the minichromosome maintenance (MCM) helicase and other factors such as Cdc45 and the associated GINS complex.The unwound single strands are protected by replication protein A (RPA) until DNA polymerase starts synthesizing DNA at the 5’ end of the strand in the same direction as the replication fork. To prevent the replication fork from falling apart, a...
Covalently Linked Protein Regulators02:04

Covalently Linked Protein Regulators

Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein.